Technical competency mapping, cGMP training administration, regulatory inspection readiness, and cross-functional SOP compliance.
Showing 85 of 85 Questions
Q1IMPORTANT
Q1. Adsorbent in Chromatography
Solid material (such as silica gel, activated alumina, or Florisil) that holds solute molecules onto its surface through intermolecular Van der Waals or dipole forces.
Q2IMPORTANT
Q2. Adsorption Chromatography
Chromatographic separation based on competitive physical or chemical adsorption interactions between solute molecules and active polar binding sites on the surface of a solid stationary phase (like silica or alumina).
Q3IMPORTANT
Q3. Alpha Value (Chromatographic Selectivity)
The ratio of retention factors (k2 / k1) of two adjacent chromatographic peaks, reflecting the thermodynamic selectivity of the stationary and mobile phase system.
Q4IMPORTANT
Q4. Anion Exchange Chromatography (AEX)
Ion-exchange mode utilizing positively charged stationary phase ligands (e.g., quaternary ammonium, Q-Sepharose) to retain negatively charged acidic proteins and DNA.
Q5IMPORTANT
Q5. Assay of Azithromycin Dihydrate by RPHPLC
Quantitative determination of active content in dosage form using validated reversed-phase liquid chromatography. Applied specifically to Azithromycin Dihydrate.
Q6IMPORTANT
Q6. Assay Specification & RPHPLC Method for Azithromycin Dihydrate
Validated chromatographic assay quantifying active chemical potency (typically 98.0% – 102.0% for drug substance, 95.0% – 105.0% for finished dosage). Specific to Azithromycin Dihydrate (Azalide 15-membered ring macrolide antibiotic).
Q7IMPORTANT
Q7. Assay Specification & RPHPLC Method for Clarithromycin
Validated chromatographic assay quantifying active chemical potency (typically 98.0% – 102.0% for drug substance, 95.0% – 105.0% for finished dosage). Specific to Clarithromycin (Semisynthetic 14-membered macrolide antibiotic).
Q8IMPORTANT
Q8. Bathochromic Shift (Red Shift)
Shift of an absorption maximum to a longer wavelength (lower energy), often caused by solvent polarity or pH changes.
Q9IMPORTANT
Q9. Breakthrough Therapy Designation
FDA program expediting development and review of drugs for serious conditions showing substantial improvement over existing therapy.
Q10IMPORTANT
Q10. Breakthrough Therapy Designation (FDA)
Expedited FDA development program for drugs intended to treat serious conditions where preliminary clinical evidence indicates substantial improvement over existing therapies.
Q11IMPORTANT
Q11. BubbleThrough / Dynamic Air Lock
Cascade air lock has high pressure on one side falling to low; Sink air lock is lower pressure than both rooms; Bubble air lock is higher than both.
Q12IMPORTANT
Q12. Chromophore
Functional group within a molecule responsible for absorbing ultraviolet or visible radiation (e.g. conjugated dienes, carbonyls, aromatics).
Q13IMPORTANT
Q13. Circular Dichroism Spectroscopy (FarUV vs NearUV)
Spectroscopic technique measuring the differential absorption of left and right circularly polarized light: Far-UV (190-250 nm) probes secondary structure; Near-UV (250-320 nm) probes tertiary structure.
Q14IMPORTANT
Q14. Circular Dichroism Spectroscopy (FarUV)
Spectroscopic technique measuring difference in absorption of left- and right-circularly polarized light between 190 and 260 nm.
Q15IMPORTANT
Q15. Content Uniformity Testing of Azithromycin Dihydrate LowDose Units
Individual chemical assay of 10 separate dosage units to confirm uniform active drug substance distribution. Applied specifically to Azithromycin Dihydrate.
Q16IMPORTANT
Q16. Content Uniformity Testing Protocol for Azithromycin Dihydrate
Harmonized USP <905> uniformity evaluation assaying 10 to 30 individual dosage units. Specific to Azithromycin Dihydrate (Azalide 15-membered ring macrolide antibiotic).
Q17IMPORTANT
Q17. Content Uniformity Testing Protocol for Clarithromycin
Harmonized USP <905> uniformity evaluation assaying 10 to 30 individual dosage units. Specific to Clarithromycin (Semisynthetic 14-membered macrolide antibiotic).
Q18IMPORTANT
Q18. Coulometric KF Cell Diaphragm
Porous ceramic frit separating anode and cathode compartments in coulometric Karl Fischer cells.
Q19IMPORTANT
Q19. Critical Process Parameters (CPPs) for Azithromycin Dihydrate
Key manufacturing operating parameters (e.g. blend time, impeller RPM, compression force, drying temp) directly governing product CQAs. Specific to Azithromycin Dihydrate (Azalide 15-membered ring macrolide antibiotic).
Q20IMPORTANT
Q20. Critical Process Parameters (CPPs) for Clarithromycin
Key manufacturing operating parameters (e.g. blend time, impeller RPM, compression force, drying temp) directly governing product CQAs. Specific to Clarithromycin (Semisynthetic 14-membered macrolide antibiotic).
Q21IMPORTANT
Q21. Cytochrome P450 2D6 Enzyme (CYP2D6)
Polymorphic hepatic enzyme metabolizing beta-blockers, antidepressants, and activating codeine prodrug into morphine.
Q22IMPORTANT
Q22. Cytochrome P450 3A4 Enzyme (CYP3A4)
Primary hepatic and intestinal microsomal enzyme responsible for metabolizing over 50% of commercial prescription drugs.
Q23IMPORTANT
Q23. Cytochrome P450 CYP2D6 Genetic Polymorphism
Polymorphic drug-metabolizing enzyme displaying profound genetic variation, categorizing patients into Poor, Intermediate, Extensive, and Ultra-Rapid Metabolizers.
Q24IMPORTANT
Q24. Cytochrome P450 CYP3A4 Isoenzyme
The most abundant phase I drug-metabolizing cytochrome P450 enzyme in human liver and intestinal mucosa, responsible for metabolizing over 50% of commercial pharmaceuticals.
Q25IMPORTANT
Q25. Derivatization in Chromatography
Chemical modification of an analyte to enhance volatility, detectability, or chromatographic behavior.
Q26IMPORTANT
Q26. Electron Capture Detector in Gas Chromatography
Highly selective GC detector utilizing a beta-emitting radioactive Nickel-63 (63Ni) foil to ionize carrier gas; electronegative halogen atoms capture electrons and reduce standing current.
Q27IMPORTANT
Q27. Elemental Impurities Risk Assessment for Azithromycin Dihydrate
Formal toxicological risk assessment under ICH Q3D evaluating potential Class 1, 2A, 2B, and 3 metal contamination via ICP-MS. Specific to Azithromycin Dihydrate (Azalide 15-membered ring macrolide antibiotic).
Q28IMPORTANT
Q28. Elemental Impurities Risk Assessment for Clarithromycin
Formal toxicological risk assessment under ICH Q3D evaluating potential Class 1, 2A, 2B, and 3 metal contamination via ICP-MS. Specific to Clarithromycin (Semisynthetic 14-membered macrolide antibiotic).
Q29IMPORTANT
Q29. Finished Product Release Specification for Azithromycin Dihydrate
Authorized regulatory document compiling all required release tests (description, identity, assay, impurities, dissolution, microbial limits). Specific to Azithromycin Dihydrate (Azalide 15-membered ring macrolide antibiotic).
Q30IMPORTANT
Q30. Finished Product Release Specification for Clarithromycin
Authorized regulatory document compiling all required release tests (description, identity, assay, impurities, dissolution, microbial limits). Specific to Clarithromycin (Semisynthetic 14-membered macrolide antibiotic).
Q31IMPORTANT
Q31. Fronting Peak in Chromatography
Asymmetric chromatographic peak where the front half is broader than the rear half (Asymmetry Factor As < 0.9 or USP Tailing T < 0.9).
Q32IMPORTANT
Q32. Gas Chromatography
Chromatography technique separating volatile compounds carried by an inert gas through a capillary column.
Q33IMPORTANT
Q33. Gas Chromatography Mass Spectrometry
Hyphenated analytical technique coupling gas chromatographic separation with electron ionization (EI) mass spectral fragmentation and mass filtering.
Q34IMPORTANT
Q34. Gas Chromatography Split vs Splitless Injection
Split injection vents a major fraction of vaporized sample (e.g. 1:50) to prevent column overloading; splitless injection directs the entire vaporized sample onto the column.
Q35IMPORTANT
Q35. Gel Permeation Chromatography
Size-exclusion chromatography technique utilizing non-aqueous mobile phases to separate polymers according to their hydrodynamic volume and molecular weight distribution (Mw, Mn).
Q36IMPORTANT
Q36. Headspace Gas Chromatography
Analytical technique where solid or liquid samples sealed in airtight vials are equilibrated at elevated temperatures, and the equilibrium vapor headspace is injected into a GC column.
Q37IMPORTANT
Q37. Headspace Gas Chromatography Partition Coefficient
Equilibrium distribution ratio of volatile analyte concentration in sample phase (Cs) to concentration in gas headspace (Cg): K = Cs / Cg.
Q38IMPORTANT
Q38. High Performance Liquid Chromatography
Analytical chromatography separating non-volatile liquid mixtures under high pressure through packed silica columns.
Chromatographic variant for polar analytes utilizing a hydrophilic polar stationary phase and a water-miscible organic mobile phase (high acetonitrile, low water).
Q48IMPORTANT
Q48. Hydrophobic Interaction Chromatography
Biomolecule separation technique utilizing weakly hydrophobic stationary phases and high salt mobile phases (e.g. ammonium sulfate) that promote hydrophobic adsorption under non-denaturing conditions.
Q49IMPORTANT
Q49. Hypsochromic Shift (Blue Shift)
Shift of an absorption maximum to a shorter wavelength (higher energy).
Q50IMPORTANT
Q50. InProcess Controls & Sampling Frequency for Azithromycin Dihydrate
Routine tests executed during manufacturing (tablet weight variation every 15 min, hardness, thickness, friability, DT every 30 min). Specific to Azithromycin Dihydrate (Azalide 15-membered ring macrolide antibiotic).
Q51IMPORTANT
Q51. InProcess Controls & Sampling Frequency for Clarithromycin
Routine tests executed during manufacturing (tablet weight variation every 15 min, hardness, thickness, friability, DT every 30 min). Specific to Clarithromycin (Semisynthetic 14-membered macrolide antibiotic).
Q52IMPORTANT
Q52. IonPair ReversedPhase Chromatography
Chromatographic technique adding an amphiphilic ionic counter-ion (e.g. Sodium Heptanesulfonate for bases, Tetrabutylammonium for acids) to the mobile phase.
Q53IMPORTANT
Q53. IonPairing Chromatography
Technique adding lipophilic ionic reagents (e.g. octane sulfonic acid, tetrabutylammonium) to retain ionic analytes on C18.
Q54IMPORTANT
Q54. Liquid Chromatography Tandem Mass Spectrometry
Analytical powerhouse combining HPLC separation with triple-quadrupole mass spectrometry operating in Selected Reaction Monitoring (SRM/MRM) mode.
Q55IMPORTANT
Q55. NearUV Circular Dichroism
CD spectroscopy covering 260 to 320 nm probing aromatic amino acid environments (Phe, Tyr, Trp) and disulfide bonds.
Q56IMPORTANT
Q56. Normal Phase Liquid Chromatography
Chromatographic mode employing a polar stationary phase (silica, amino, cyano) and a non-polar organic mobile phase (hexane, heptane, isopropanol).
Q57IMPORTANT
Q57. Protein A Affinity Chromatography
Primary downstream purification capture step binding antibody Fc region with high selectivity (> 95% purity in single step).
Q58IMPORTANT
Q58. Related Substances & Degradation Profile for Azithromycin Dihydrate
Gradient liquid chromatographic method resolving synthesis impurities and degradation products below ICH Q3A/B qualification thresholds. Specific to Azithromycin Dihydrate (Azalide 15-membered ring macrolide antibiotic).
Q59IMPORTANT
Q59. Related Substances & Degradation Profile for Clarithromycin
Gradient liquid chromatographic method resolving synthesis impurities and degradation products below ICH Q3A/B qualification thresholds. Specific to Clarithromycin (Semisynthetic 14-membered macrolide antibiotic).
Q60IMPORTANT
Q60. Related Substances Testing of Azithromycin Dihydrate by Gradient HPLC
Chromatographic separation and quantitation of synthesis intermediates and degradation impurities. Applied specifically to Azithromycin Dihydrate.
Q61IMPORTANT
Q61. Residual Solvents Limit Testing for Azithromycin Dihydrate
Headspace gas chromatography with flame ionization detection (HS-GC-FID) quantitating Class 1, 2, and 3 process solvents. Specific to Azithromycin Dihydrate (Azalide 15-membered ring macrolide antibiotic).
Q62IMPORTANT
Q62. Residual Solvents Limit Testing for Clarithromycin
Headspace gas chromatography with flame ionization detection (HS-GC-FID) quantitating Class 1, 2, and 3 process solvents. Specific to Clarithromycin (Semisynthetic 14-membered macrolide antibiotic).
Q63IMPORTANT
Q63. Resolution (Chromatography)
Measure of the separation between two adjacent chromatographic peaks (Rs = 2 * (tR2 – tR1) / (W1 + W2)).
Q64IMPORTANT
Q64. Resolution Factor in Chromatography
Quantitative measure of the degree of separation between two adjacent chromatographic peaks: Rs = 2 * (tR2 – tR1) / (W1 + W2).
The predominant chromatographic mode in pharma analysis, utilizing a non-polar stationary phase (C18 / C8 bonded silica) and a polar aqueous-organic mobile phase (water/buffer with acetonitrile or methanol).
Q66IMPORTANT
Q66. ReversedPhase IonPairing Chromatography
Adding alkyl sulfonates (for bases) or tetraalkylammonium salts (for acids) to reverse phase mobile phase to retain ions.
Q67IMPORTANT
Q67. Sanitary Diaphragm Valve (Zero Dead Leg)
Valve with PTFE diaphragm sealing directly against the weir of the process pipe, eliminating stagnant uncleaned pockets.
Q68IMPORTANT
Q68. SignaltoNoise Ratio in Chromatography
The ratio comparing the peak height signal of an analyte to the peak-to-peak baseline background noise across a blank region of the chromatogram.
Q69IMPORTANT
Q69. Silanol Activity in Chromatography
Presence of unreacted acidic isolated silanol groups (Si-OH) on silica surface participating in unwanted cation-exchange with amines.
Q70IMPORTANT
Q70. Size Exclusion Chromatography
Chromatographic mode where molecules are separated strictly based on their hydrodynamic molecular size as they pass through porous gel filtration beads.
Q71IMPORTANT
Q71. SizeExclusion Chromatography Column for Aggregates
Column packed with silica or polymer particles with calibrated pore sizes (e.g., 200 to 300 Angstroms) for protein sizing.
Q72IMPORTANT
Q72. Snyder Chromatographic Selectivity Triangle
Classification characterizing solvent selectivity based on three dominant interaction properties: proton donor acidity (?), proton acceptor basicity (?), and dipolarity (?*).
Q73IMPORTANT
Q73. Stability Testing of Azithromycin Dihydrate under Accelerated Conditions (40 deg C/75% RH)
Evaluation of chemical, physical, and microbiological stability under accelerated environmental stress over 6 months. Applied specifically to Azithromycin Dihydrate.
Q74IMPORTANT
Q74. Stability Testing Protocol (ICH Q1A) for Azithromycin Dihydrate
Testing schedule (0, 3, 6, 9, 12, 18, 24, 36 months) evaluating long-term (25 deg C/60% RH) and accelerated (40 deg C/75% RH) chemical stability. Specific to Azithromycin Dihydrate (Azalide 15-membered ring macrolide antibiotic).
Q75IMPORTANT
Q75. Stability Testing Protocol (ICH Q1A) for Clarithromycin
Testing schedule (0, 3, 6, 9, 12, 18, 24, 36 months) evaluating long-term (25 deg C/60% RH) and accelerated (40 deg C/75% RH) chemical stability. Specific to Clarithromycin (Semisynthetic 14-membered macrolide antibiotic).
Q76IMPORTANT
Q76. Tetrahydrofuran in Chromatography
Strong organic solvent with ether oxygen conferring unique selectivity for polymer and lipid separations.
Q77IMPORTANT
Q77. Thin Layer Chromatography Rf Value
Retention factor in planar chromatography: Rf = Distance traveled by substance / Distance traveled by solvent front.
Q78IMPORTANT
Q78. Time Synchronization
Automatic synchronization of system internal clocks across all networked laboratory computers and instruments to a secure master network clock.
Q79IMPORTANT
Q79. Triethylamine in Chromatography
Volatile amine additive acting as competing base to block active acidic silanol groups on older silica columns.
Q80IMPORTANT
Q80. TwoDimensional Liquid Chromatography (2DLC)
Technique transferring fractions from first column (e.g. SEC or IEX) onto second orthogonal column (e.g. RP) via switching valve.
Q81IMPORTANT
Q81. UltraHigh Performance Liquid Chromatography
Liquid chromatography operating at extreme fluid pressures (up to 15,000 psi / 1000 bar) utilizing sub-2-micrometer stationary phase packing particles.
Q82IMPORTANT
Q82. USP <621> Chromatography
Compendial general chapter defining chromatographic definitions, calculations, system suitability, and allowable method adjustments.
Q83IMPORTANT
Q83. USP <621> Chromatography Harmonization
General chapter detailing chromatographic definitions, system suitability formulas, and permissible adjustments to mobile phase, column dimensions, and flow rate without requiring revalidation.
Dissolution apparatus pumping fresh or circulating dissolution medium upward through a vertical flow cell containing sample beads or tablets at controlled flow rates.
Q85IMPORTANT
Q85. Zeta Potential Colloidal Stability Threshold
The electrokinetic potential at the slipping plane of a colloidal particle moving under an applied electric field.